Non-viral gene delivery systems.
Non-viral gene delivery systems have the potential to create viable pharmaceuticals from nucleic acids. These DNA delivery systems contain lipids and/or cationic polymers. In order for these systems to be developed into commercial products, several barriers must be overcome. These include obstacles in manufacturing, formulation and stability. In vivo, problems of extracellular non-specific interactions and intracellular trafficking to the nucleus are also encountered. Recent progress has been made in overcoming these issues.
Davis
Mark E
ME
Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA. mdavis@cheme.caltech.edu
D001693:Biological Transport, Active; D002467:Cell Nucleus / Q000378:metabolism; D004247:DNA / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism*; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004355:Drug Stability; D004705:Endocytosis / Q000502:physiology; D018014:Gene Transfer Techniques / Q000009:adverse effects; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends*; D005822:Genetic Vectors / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D011108:Polymers / Q000378:metabolism
D004337:Drug Carriers; D011108:Polymers; D004247:DNA